Skip to main content

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is an American commercial-stage biopharmaceutical company focused on rare genetic diseases of obesity. The company discovers, develops, and commercializes therapies targeting the melanocortin-4 receptor pathway to restore energy balance in patients with hyperphagia and severe obesity. Main revenue drivers stem from sales of setmelanotide, marketed under the brand name Imcivree, for conditions such as Bardet-Biedl syndrome and pro-opiomelanocortin deficiency. Rhythm Pharmaceuticals serves specialized medical markets, healthcare providers, and patients across North America, Europe, and international territories. The company occupies a pioneer position in precision medicine for rare genetic endocrine disorders. Headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals Inc is listed on the Nasdaq Stock Market.

8 of the funds FundTelligence covers report a position in Rhythm Pharmaceuticals.

Legal name
Rhythm Pharmaceuticals Inc
Sector
Health Care
Country
United States
Funds holding it
8
Exposure themes
Genetic Obesity, Obesity, Obesity & Metabolic Health

Funds holding Rhythm Pharmaceuticals

Loading...